We have located links that may give you full text access.
Aortic valve replacement with and without concomitant coronary artery bypass surgery in the elderly: risk factors related to long-term survival.
Croatian Medical Journal 2000 December
AIM: Preoperative coronary angiography often reveals significant coronary artery lesions in elderly people (>75 years of age) referred to hospital for aortic valve replacement (AVR). However, the possible benefit of concomitant coronary artery bypass grafting (CABG) in elderly is still under debate. In an effort to contribute to this discussion, we evaluated our data on elderly patients after aortic valve replacement.
METHODS: Between January 1990 and December 1993, 219 patients, aged 75 years and older, underwent AVR with or without concomitant CABG at our Department. There were 121 patients in the AVR group and 98 patients in the AVR+CABG group. There was no significant difference between the two groups in their age, sex valve type, valve size, and presence of diabetes. Five variables (concomitant CABG, age, sex, and type and size of prosthesis) were investigated with regard to long-term survival assessed by the Kaplan-Meier analysis. Group comparisons of survival were made with the Cox-Mantel log-rank test.
RESULTS: Early mortality (<30 days) was 0.8% in the AVR group and 4.1% in the AVR+CABG group. Overall actuarial survival was 77.7+/-4.4% at 52 months. There was significantly longer survival in patients with mechanical valve implant in the AVR group. None of the other 5 investigated variables had a significant influence on the long-term survival.
CONCLUSION: Our results suggest that AVR done in elderly is a treatment with excellent surgical results. We could not identify concomitant CABG as a predictor of poor long-term surgical outcome.
METHODS: Between January 1990 and December 1993, 219 patients, aged 75 years and older, underwent AVR with or without concomitant CABG at our Department. There were 121 patients in the AVR group and 98 patients in the AVR+CABG group. There was no significant difference between the two groups in their age, sex valve type, valve size, and presence of diabetes. Five variables (concomitant CABG, age, sex, and type and size of prosthesis) were investigated with regard to long-term survival assessed by the Kaplan-Meier analysis. Group comparisons of survival were made with the Cox-Mantel log-rank test.
RESULTS: Early mortality (<30 days) was 0.8% in the AVR group and 4.1% in the AVR+CABG group. Overall actuarial survival was 77.7+/-4.4% at 52 months. There was significantly longer survival in patients with mechanical valve implant in the AVR group. None of the other 5 investigated variables had a significant influence on the long-term survival.
CONCLUSION: Our results suggest that AVR done in elderly is a treatment with excellent surgical results. We could not identify concomitant CABG as a predictor of poor long-term surgical outcome.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app